Neoadjuvant, Adjuvant and Perioperative Treatment in Early-Stage Non-Small Cell Lung Cancer (NSCLC) with Actionable Genomic Alterations: Current Landscape and Future Perspectives.

Cancers (Basel) · 2026 · PMC12897308 · PMID 41681965

Europe PMC DOI

hedged sentences

0.0510

closest p · 1.0× alpha

0.0510

boldest claim

The sentences

borderline significantp = 0.051so close (0.05 < p ≤ 0.1)

The 3-year DFS was 91.7% in the alectinib group and 60.7% in the ChT group, albeit with a borderline significant benefit in DFS (HR: 0.17, 95% CI 0.02–1.28, p = 0.051), most likely due to the small sample size.

also in 7,848 other papers

a positive trendno p-value reported

Finally, regarding OS results, there was a positive trend in the ITT population with adjuvant alectinib compared to placebo with 4 years of median follow-up (4-year OS 98.4% vs. 92.4%, HR: 0.40, 95% CI 0.12–1.32) [ 71 ].

also in 7,469 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.